IND Application for NTS071, Nutshell Therapeutics' p53 Y220C Allosteric Reactivator, Received US FDA clearance ...Middle East

SHANGHAI, May 4, 2025 /PRNewswire/ -- On April 23, 2025, Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial in the United States for its NTS071, a novel small molecule allosteric reactivator targeting p53 Y220C mutation....

Read More Details
Finally We wish PressBee provided you with enough information of ( IND Application for NTS071, Nutshell Therapeutics' p53 Y220C Allosteric Reactivator, Received US FDA clearance )

Also on site :

• More man-portable air defence missile systems on the way amid India-Pak tensions
• Catholic Bishops Issue Direct Response to Trump's Polarizing Pope Photo
• ‘Saturday Night Live’ Opens With Donald Trump Signing Executive Orders, Including The “Belichick Law”: “Old Men Can Now Date Far Younger Women”